Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by ChromaDex Corporation
< Previous
1
2
3
Next >
ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category
December 03, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
November 14, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
November 07, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
October 31, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
October 28, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
October 24, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Participate in the 17th Annual LD Micro Main Event
October 23, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)
October 15, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
September 26, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Appoints Ozan Pamir as Chief Financial Officer
September 20, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
September 10, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
September 09, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
August 23, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
August 19, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
August 07, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
August 05, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
July 24, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
July 23, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
July 22, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
July 16, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Join Russell 2000® Index
July 01, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
June 24, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
June 13, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
June 07, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
June 04, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
May 23, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
May 22, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Corporation Reports First Quarter 2024 Financial Results
May 08, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
April 25, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
April 30, 2024
From
ChromaDex Corporation
Via
Business Wire
Tickers
CDXC
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.